Skip to main content

New Clinical Trial: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform..

*November 2020*

This new clinical trial is for those people whose EGFR lung cancer has transformed to small cell lung cancer.This trial covers travel expenses as well. Any questions can be directed to Dr. Anish Thomas at: (In addition to this trial, there are other NCI trials for small cell lung cancer that patients with transformation could qualify for.)  Learn more about this clinical trial.